| Positive Rankings |
90 Day Gain
Proteostasis Therapeutics rank is 63 |
Low vPut/Call
Proteostasis Therapeutics has a low Put/Call ratio of 0.18 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Proteostasis Therapeutics is ranked 371. |
Up Ratings Revision
During the past month, the average analyst's rating or recommendation has increased. Among companies that have been upgraded within the past month, Proteostasis Therapeutics is ranked 615. |
Debt-to-Equity
Proteostasis Therapeutics rank is 831 |
| Negative Rankings |
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Proteostasis Therapeutics is ranked 159. |
Negative Net Margin
Proteostasis Therapeutics rank is 163 |
Price-to-Sales
Proteostasis Therapeutics rank is 165 |
Down EPS Surprise
Proteostasis Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings. |
Negative ROE
Proteostasis Therapeutics rank is 393 |
Negative ROA
Proteostasis Therapeutics rank is 437 |
10 Day Loss
Proteostasis Therapeutics rank is 629 |
High Put/Call
Proteostasis Therapeutics has a high Put/Call ratio of 0.74 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Proteostasis Therapeutics is ranked 1375. |
Price-to-Book
Proteostasis Therapeutics rank is 1588 |
